President Donald Trump has nominated Dr. Susan Monarez, the acting director of the Centers for Disease Control and Prevention (CDC), to lead the agency permanently. Monarez, who has served as acting director since January following the withdrawal of Dr. Dave Weldon’s nomination, holds a Ph.D. in microbiology and immunology. She previously served as the deputy director of the Advanced Research Projects Agency for Health (ARPA-H), focusing on innovative health research
This nomination is significant as it marks the first time a CDC director nominee will require Senate confirmation, following a law change in 2022. Monarez’s appointment comes at a time when the CDC is addressing public health challenges, including outbreaks of avian flu and measles, as well as rising vaccine hesitancy.
However, Monarez’s tenure has faced internal challenges. Some CDC staff have expressed concerns about her visibility and leadership, describing her as more of a “placeholder” than a proactive leader. There are also worries about potential funding and workforce cuts within the agency.
Complicating matters, Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. has initiated a restructuring plan that includes significant layoffs across multiple health agencies, including the CDC and the National Institutes of Health (NIH). Approximately 1,300 employees, or 10% of the CDC workforce, have been laid off, raising concerns about the agency’s capacity to respond to public health threats.
Critics argue that these cuts could hinder the CDC’s effectiveness, especially given the ongoing public health challenges. The closure of the Office of Long Covid Research and Practice within HHS has also raised concerns about the administration’s commitment to addressing long-term health impacts of the pandemic.
As Monarez’s nomination moves forward, it will be crucial to assess her ability to navigate these internal challenges and restore confidence in the CDC’s role in safeguarding public health.
